• Vitórica-Yrezábal, Iñigo J.
• Cristobal-Cueto, Pablo
• Hidalgo, Tania
• Horcajada, Patricia
• Rodríguez-Diéguez, Antonio
• García-García, Amalia
• Rojas, Sara

Abstract

<jats:title>Abstract</jats:title><jats:p>Two new lanthanide-complexes based on the 5-nitropicolinate ligand (5-npic) were obtained and fully characterized. Single-crystal X-ray diffraction revealed that these compounds are isostructural to a Dy-complex, previously published by us, based on dinuclear monomers link together with an extended hydrogen bond network, providing a final chemical formula of [Ln<jats:sub>2</jats:sub>(5-npic)<jats:sub>6</jats:sub>(H<jats:sub>2</jats:sub>O)<jats:sub>4</jats:sub>]·(H<jats:sub>2</jats:sub>O)<jats:sub>2</jats:sub>, where Ln = Dy <jats:bold>(1)</jats:bold>, Gd <jats:bold>(2)</jats:bold>, and Tb <jats:bold>(3)</jats:bold>. Preliminary photoluminescent studies exhibited a ligand-centered emission for all complexes. The potential antitumoral activity of these materials was assayed in a prostatic cancer cell line (PC-3; the 2nd most common male cancerous disease), showing a significant anticancer activity (50–60% at 500 μg·mL<jats:sup>−1</jats:sup>). In turn, a high biocompatibility by both, the complexes and their precursors in human immunological HL-60 cells, was evidenced. In view of the strongest toxic effect in the tumoral cell line provided by the free 5-npic ligand (~ 40–50%), the overall anticancer complex performance seems to be triggered by the presence of this molecule.</jats:p><jats:p><jats:bold>Graphical Abstract</jats:bold></jats:p>

Topics

• compound
• x-ray diffraction
• Hydrogen
• Lanthanide
• biocompatibility